GlassScriptPhysician profile
Eugene Verkhovsky
NPI 1164836516
$8,703.08
in general payments reported to CMS, 2019-2025
39 companies · $1,944 in 2025
The $1,944 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.45 · 2022: $1,769 · 2023: $2,492 · 2024: $2,443 · 2025: $1,944.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,808 · Education: $71.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,807.50 |
| Education | $71.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,278.84 | 2022-2025 | Stelara, Tremfya, Simponi Aria |
| Abbvie INC. | $1,125.25 | 2022-2025 | Skyrizi, Linzess, Rinvoq |
| Takeda Pharmaceuticals U.S.A., INC. | $1,065.24 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $697.22 | 2022-2025 | Xifaxan, Trulance, Plenvu |
| Genzyme Corporation | $663.66 | 2023-2025 | |
| Pfizer INC. | $541.64 | 2022-2025 | |
| Gilead Sciences, INC. | $489.07 | 2023-2025 | |
| Celgene Corporation | $362.99 | 2022-2024 | Zeposia |
| Lilly USA, LLC | $273.94 | 2023-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $233.87 | 2024-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $186.97 | 2024-2025 | Iqirvo, Bylvay |
| Medtronic, INC. | $184.61 | 2022 | |
| Ferring Pharmaceuticals INC. | $161.15 | 2022-2025 | Rebyota, Cimzia |
| Ardelyx, INC. | $150.98 | 2022-2023 | Ibsrela |
| Madrigal Pharmaceuticals | $143.97 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 38 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$13,142.76 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Verkhovsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.